72 related articles for article (PubMed ID: 23635474)
1. Expression of apoptosis- and vitamin D pathway-related genes in hepatocellular carcinoma.
Fingas CD; Altinbas A; Schlattjan M; Beilfuss A; Sowa JP; Sydor S; Bechmann LP; Ertle J; Akkiz H; Herzer K; Paul A; Gerken G; Baba HA; Canbay A
Digestion; 2013; 87(3):176-81. PubMed ID: 23635474
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma.
Ikeguchi M; Hirooka Y; Kaibara N
Cancer; 2002 Nov; 95(9):1938-45. PubMed ID: 12404288
[TBL] [Abstract][Full Text] [Related]
3. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
Dong-Dong L; Xi-Ran Z
Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
[TBL] [Abstract][Full Text] [Related]
4. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
[TBL] [Abstract][Full Text] [Related]
6. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
7. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma.
Fleischer B; Schulze-Bergkamen H; Schuchmann M; Weber A; Biesterfeld S; Müller M; Krammer PH; Galle PR
Int J Oncol; 2006 Jan; 28(1):25-32. PubMed ID: 16327976
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of ZBP-89 and its prognostic significance in hepatocellular carcinoma.
Zhang CZ; Cao Y; Yun JP; Chen GG; Lai PB
Histopathology; 2012 Jun; 60(7):1114-24. PubMed ID: 22372401
[TBL] [Abstract][Full Text] [Related]
9. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
[TBL] [Abstract][Full Text] [Related]
10. Central genetic alterations common to all HCV-positive, HBV-positive and non-B, non-C hepatocellular carcinoma: a new approach to identify novel tumor markers.
Kurokawa Y; Honma K; Takemasa I; Nakamori S; Kita-Matsuo H; Motoori M; Nagano H; Dono K; Ochiya T; Monden M; Kato K
Int J Oncol; 2006 Feb; 28(2):383-91. PubMed ID: 16391793
[TBL] [Abstract][Full Text] [Related]
11. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
[TBL] [Abstract][Full Text] [Related]
12. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines.
Noda K; Miyoshi E; Gu J; Gao CX; Nakahara S; Kitada T; Honke K; Suzuki K; Yoshihara H; Yoshikawa K; Kawano K; Tonetti M; Kasahara A; Hori M; Hayashi N; Taniguchi N
Cancer Res; 2003 Oct; 63(19):6282-9. PubMed ID: 14559815
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of decreased nidogen-2 expression in the tumor tissue and serum of patients with hepatocellular carcinoma.
Cheng ZX; Huang XH; Wang Q; Chen JS; Zhang LJ; Chen XL
J Surg Oncol; 2012 Jan; 105(1):71-80. PubMed ID: 21815147
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma.
Fautrel A; Andrieux L; Musso O; Boudjema K; Guillouzo A; Langouët S
J Hepatol; 2005 Aug; 43(2):288-93. PubMed ID: 15922480
[TBL] [Abstract][Full Text] [Related]
16. Relationship between expression of Smac and Survivin and apoptosis of primary hepatocellular carcinoma.
Bao ST; Gui SQ; Lin MS
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):580-3. PubMed ID: 17085346
[TBL] [Abstract][Full Text] [Related]
17. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma.
Kriegl L; Jung A; Engel J; Jackstadt R; Gerbes AL; Gallmeier E; Reiche JA; Hermeking H; Rizzani A; Bruns CJ; Kolligs FT; Kirchner T; Göke B; De Toni EN
Clin Cancer Res; 2010 Nov; 16(22):5529-38. PubMed ID: 20889918
[TBL] [Abstract][Full Text] [Related]
18. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.
Sieghart W; Losert D; Strommer S; Cejka D; Schmid K; Rasoul-Rockenschaub S; Bodingbauer M; Crevenna R; Monia BP; Peck-Radosavljevic M; Wacheck V
J Hepatol; 2006 Jan; 44(1):151-7. PubMed ID: 16289418
[TBL] [Abstract][Full Text] [Related]
19. [Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof].
Shen HW; Wu YL; Peng SY
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):744-7. PubMed ID: 12899749
[TBL] [Abstract][Full Text] [Related]
20. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
